These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 27059714

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Impact of 2015 Update to the Beers Criteria on Estimates of Prevalence and Costs Associated with Potentially Inappropriate Use of Antimuscarinics for Overactive Bladder.
    Suehs BT, Davis C, Ng DB, Gooch K.
    Drugs Aging; 2017 Jul; 34(7):535-543. PubMed ID: 28540648
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Antimuscarinic Medication Use in Elderly Patients with Overactive Bladder.
    Kachru N, Sura S, Chatterjee S, Aparasu RR.
    Drugs Aging; 2016 Oct; 33(10):755-763. PubMed ID: 27681701
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries.
    Aparasu RR, Sura S, Earla JR, Shiozawa A, Ng DB, Schermer CR.
    Adv Ther; 2020 Aug; 37(8):3584-3605. PubMed ID: 32638205
    [Abstract] [Full Text] [Related]

  • 10. A prospective study of elderly initiating mirabegron versus antimuscarinics: Patient reported outcomes from the Overactive Bladder Satisfaction Scales and other instruments.
    Bunniran S, Davis C, Kristy R, Ng D, Schermer CR, Uribe C, Suehs BT.
    Neurourol Urodyn; 2018 Jan; 37(1):177-185. PubMed ID: 28370541
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives.
    Wielage RC, Perk S, Campbell NL, Klein TM, Posta LM, Yuran T, Klein RW, Ng DB.
    J Med Econ; 2016 Dec; 19(12):1135-1143. PubMed ID: 27326725
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
    Chapple CR, Nazir J, Hakimi Z, Bowditch S, Fatoye F, Guelfucci F, Khemiri A, Siddiqui E, Wagg A.
    Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
    [Abstract] [Full Text] [Related]

  • 17. Use of health care resources and associated costs in non-institutionalized vulnerable elders with overactive bladder treated with antimuscarinic agents in the usual medical practice.
    Sicras-Mainar A, Rejas-Gutiérrez J, Navarro-Artieda R, Aguado-Jodar A, Ruíz-Torrejón A.
    Actas Urol Esp; 2014 Oct; 38(8):530-7. PubMed ID: 24630426
    [Abstract] [Full Text] [Related]

  • 18. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.
    Wagg A, Compion G, Fahey A, Siddiqui E.
    BJU Int; 2012 Dec; 110(11):1767-74. PubMed ID: 22409769
    [Abstract] [Full Text] [Related]

  • 19. Mirabegron and antimuscarinic use in frail overactive bladder patients in the United States Medicare population.
    Johnson TM, Walker D, Lockefeer A, Jiang B, Nimke D, Lozano-Ortega G, Kimura T.
    Neurourol Urodyn; 2022 Nov; 41(8):1872-1889. PubMed ID: 36098417
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.